INSTITUTO FINLAY. CENTRO DE INVESTIGACION- PRODUCCION DE SUEROS Y VACUNAS.
发明人:
PEREZ MARTIN, OLIVER GERMAN,ROMEU ALVAREZ, BELKIS,LASTRE GONZALEZ, MIRIAM DE SAN JUAN BOSCO,ZAYAS VIGNIER, CARIDAD,GONZALEZ AZNAR, ELIZABETH,BALBOA GONZALEZ, JULIO ANTONIO,CABRERA BLANCO, OSMIR,CUELLO
申请号：
CUCU2012/000006
公开号：
WO2013/064129A1
申请日:
2012.11.02
申请国别(地区):
WO
年份:
2013
代理人:
摘要：
The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.La invención provee composiciones inmunogénicas para aplicaciones mucosales yparenterales comprendiendo (1) un sacárido capsular único o múltiples bacteriano noconjugados y (2) potentes adyuvantes. Polisacáridos u oligosacáridos planos son preferidos sin excluir la adición de los potentes adyuvantes a polisacáridos conjugados. Es preferido que los adyuvantes sean los AFCox (Adjuvant Finlay Cocleato familia x) o AFPLx (Proteoliposoma familia x). Es preferido la vía mucosal sin excluir la parenteral o combinaciones de estas. La invención también provee composiciones inmunogénicas a) un antígeno sacarídico capsular de serogrupo C o serogrupo A de. Neisseria meningitidis, b) los ad
